Answers are grounded in this paper and cite their sources.
Expert panel discusses digital health's impact on GH therapy for children, highlighting risks and benefits.
Digital health technologies have gained acceptance in paediatric growth hormone (GH) therapy, supporting patients and caregivers in their treatment journey with healthcare professionals (HCPs) playing a pivotal role. Understanding HCPs' perspectives regarding the adoption and recommendation of digital health devices with a connected ecosystem for remote monitoring of real-time adherence is essential for aiding clinical decisions and timely interventions. The results from a participatory workshop in Taiwan involving nine paediatric endocrinologists, exploring the risks and benefits of integrating digital health solutions such as Aluetta® with Smartdot™ and Growzen™ ecosystem (Merck Healthcare KGaA, Darmstadt, Germany) for GH therapy are presented. These findings emphasise the importance of novelty in digitalisation and evidence-based treatment strategies to motivate patients achieve growth improvement.
No takes yet. Share an insight, caveat, or question.
Koledova et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: